Modelling selective activation of small myelinated nerve fibres using a monopolar point electrode

The aim of this study is to investigate theoretically the possibility for activation of small myelinated nerve fibres without activating larger ones when stimulating a nerve fibre bundle using a monopolar point electrode. Therefore, the sensitivity of excitation and blocking threshold currents of nerve fibres to fibre diameter, electrode-fibre distance and pulse duration has been simulated by a computer model. A simple infinite, homogeneous volume conductor and a cathodal point source were used in combination with a model representing the electrical properties of a myelinated nerve fibre. The results show that selective activation of small myelinated fibres may be possible in a region at some distance from the electrode

Front Cover

Scholar-athlete

Radiolabeled monoclonal antibody G250 in renal-cell carcinoma

Contains fulltext : 20983___.PDF (publisher's version ) (Open Access

Niertransplantatie: chirurgische, in het bijzonder urologische, aspecten

Contains fulltext : mmubn000001_13784347x.pdf (publisher's version ) (Open Access)Promotores : W. Moonen en P. Wijdeveld198 p

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for

Item does not contain fulltex

Endocrine approaches in the therapy of prostate carcinoma.

Contains fulltext : 48272.pdf (publisher's version ) (Open Access)At present, the management of non-organ confined prostate cancer, whether it is a recurrence or metastasis, continues to evolve based on prostate cancer detection using prostate-specific antigen and the development of medications as alternatives for the classical orchiectomy, which induced irreversible implications for quality of life. Diethylstilbestrol therapy was associated with cardiovascular side-effects; GnRH agonists were able to create a castration level, but again considerable side-effects were described. Combination therapies using antiandrogens and GnRH agonists do not improve survival and have additional toxicity. GnRH antagonists, which also suppress FSH, represent the latest class of agents introduced for hormonal treatment, but phase III studies with survival data are not yet available. In spite of all these achievements, hormonal manipulation has resulted in only modest improvements during recent decades and new targets are needed to improve the clinical outcome. Selectively modifying the androgen receptor is currently one of the most promising developments

Medical management of BPH: the debate continues.

Contains fulltext : 50587.pdf (publisher's version ) (Closed access